Dr Mais Hussein

This session examines how breakthrough GLP-1 receptor agonists and novel combination therapies are transforming obesity treatment paradigms, elevating patient outcomes, reshaping clinical expectations, and establishing obesity as a medically manageable chronic disease requiring long-term pharmaceutical intervention.

Key Takeaways:

• Understanding how advanced GLP-1s and dual/triple agonists achieve superior weight loss and metabolic improvements, including their effects on appetite regulation, insulin sensitivity, and cardiovascular benefits beyond traditional interventions.

• Navigating prescribing guidelines, managing patient expectations for long-term therapy, addressing access and affordability challenges, and integrating pharmacotherapy with lifestyle interventions for optimal sustainable outcomes.

How nutritionists and psychologists collaborate to develop individualised treatment strategies, integrating tailored dietary approaches based on metabolic profiles with psychological interventions addressing behavioural patterns, emotional eating, and sustainable lifestyle change.